Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorth Atl.smlr Regulatory News (NAS)

Share Price Information for North Atl.smlr (NAS)

Share Price is delayed by 15 minutes
Get Live Data
400.00    5.00 (1.27%)
Bid:
396.00
Ask:
400.00
Spread: 4.00 (1.01%)
Market Cap: £508.64m
NAS Live PriceLast checked at - London Stock Exchange

Intraday North Atl.smlr Share Chart

Statement re Shareholder Engagement

20 Dec 2022 07:00

RNS Number : 2208K
North Atlantic Smlr Co Inv Tst PLC
20 December 2022
 

North Atlantic Smaller Companies Investment Trust PLC

(the "Company")

 

20 December 2022

 

 

Further to the Company's Results of Annual General Meeting announcement on 21 June 2022, the Company announced that over 20% of shareholders voting on resolution 14 concerning the waiver of Rule 9 had voted against the resolution. Resolution 14 was put to the Meeting as a resolution of the independent shareholders of the Company. As a result, 9,455,336 of the ordinary shares in issue were eligible to vote on this resolution, these shares not being held by the Concert Party (as defined in the Notice of AGM). The waiver of Rule 9 granted by Resolution 14 permits the Concert Party's interest in the Company's shares to increase from 30.78% to a maximum of 34.21% (in each case representing 4,205,664 ordinary shares) as a result of the share buyback authorised by Resolution 12 without requiring the Concert Party to make a mandatory offer for the other shareholders' shares. 

 

Under the FRC's UK Corporate Governance Code, companies receiving such a vote against a resolution should publish, no later than six months after the shareholder meeting, an update on the views received from shareholders and actions taken by the Company. 

 

Following an extensive analysis of the Company's Shareholder Register, the Company have established that the majority of the voting shares received against the waiver of Rule 9 are held in nominee accounts, many of which rely on shareholder advisory consultants to determine their voting. This means that underlying investors are recommended to vote against share buybacks in principle as the shareholder advisory consultants are concerned about what they see as the Concert Party's potential creeping control of the Company. Whilst this is a valid concern for a trading company, the Directors do not believe this is so for an investment trust.

 

The Board have been working to positively engage with the underlying Shareholders and are accelerating their Investor Relations efforts in this regard and continue to do so. The Directors expect to commence a further outreach campaign to engage with any dissenting Shareholders in the coming months and to help resolve any concerns they may have. The outcome of this initiative will be published in the Company's Annual Report next spring. In the meantime, the Board believe that it is overwhelmingly in the best interest of all Shareholders that the buyback programme continues. 

 

 

 

Contact:

Kin Company Secretarial Limited, Company Secretary

020 8819 6486

companysecretary@kincosec.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRQKLFFLLLLFBD
Date   Source Headline
30th Sep 20257:00 amRNSHalf-year Report
29th Sep 20257:00 amRNSTransaction in Own Shares and TVR
22nd Sep 202510:34 amRNSTransaction in Own Shares and TVR
18th Sep 20257:00 amRNSChange of Corporate Broker
12th Sep 20253:58 pmRNSNet Asset Value(s)
14th Aug 202511:04 amRNSNet Asset Value(s)
6th Aug 20259:57 amRNSTransaction in Own Shares and TVR
15th Jul 20259:34 amRNSNet Asset Value(s)
7th Jul 20251:00 pmRNSTransaction in Own Shares and TVR
7th Jul 202511:34 amRNSTransaction in Own Shares and TVR
19th Jun 20259:51 amRNSTransaction in Own Shares nad TVR
13th Jun 20253:52 pmRNSNet Asset Value(s)
12th Jun 20251:50 pmRNSShare Split and Total Voting Rights
12th Jun 20251:46 pmRNSResult of AGM
9th Jun 202510:45 amRNSTransaction in Own Shares and TVR
2nd Jun 20251:15 pmRNSTransaction in Own Shares and TVR
30th May 202511:01 amRNSTransaction in Own Shares and TVR
27th May 20253:26 pmRNSTransaction in Own Shares and TVR
23rd May 20251:44 pmRNSCompany Secretary Change
16th May 20257:00 amRNSNet Asset Value(s)
15th May 20257:00 amRNSAnnual Financial Report & Notice of AGM
7th May 20257:00 amRNSFinal Results
16th Apr 20257:00 amRNSNet Asset Value(s)
3rd Apr 202510:35 amRNSTransaction in Own Shares and TVR
31st Mar 20259:44 amRNSTransaction in Own Shares and TVR
24th Mar 20259:13 amRNSTransaction in Own Shares and TVR
18th Mar 20253:15 pmRNSNet Asset Value(s)
3rd Mar 20252:17 pmRNSTransaction in Own Shares and TVR
27th Feb 20257:00 amRNSDividend Declaration
17th Feb 202512:49 pmRNSTransaction in Own Shares and TVR
14th Feb 20259:26 amRNSNet Asset Value(s)
10th Feb 202511:05 amRNSTransaction in Own Shares and TVR
15th Jan 202511:10 amRNSDirector Declaration
15th Jan 202511:01 amRNSDirector Declaration
15th Jan 202510:39 amRNSNet Asset Value(s)
12th Dec 20241:48 pmRNSNet Asset Value(s)
29th Nov 202411:57 amRNSTransaction in Own Shares
25th Nov 202410:10 amRNSTransaction in Own Shares
15th Nov 202410:57 amRNSNet Asset Value(s)
11th Nov 202410:30 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSDirector/PDMR Shareholding
28th Oct 202411:50 amRNSNet Asset Value(s)
28th Oct 20247:00 amRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSInvestor Presentation via Investor Meet Company
3rd Oct 202411:51 amRNSInvestment Update: Performance Chemicals
3rd Oct 20247:00 amRNSTransaction in Own Shares
26th Sep 20247:00 amRNSHalf-year Report - Replacement
25th Sep 20247:00 amRNSHalf-year Report
13th Sep 20247:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.